Thirty-Day Results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry: A European Registry of Transcatheter Aortic Valve Implantation Using the Edwards SAPIEN Valve

Transcatheter aortic valve implantation was developed to mitigate the mortality and morbidity associated with high-risk traditional aortic valve replacement. The Edwards SAPIEN valve was approved for transcatheter aortic valve implantation transfemoral delivery in the European Union in November 2007...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2010-07, Vol.122 (1), p.62-69
Main Authors: THOMAS, Martyn, SCHYMIK, Gerhard, ANDERSON, William N, WENDLER, Olaf, WALTHER, Thomas, HIMBERT, Dominique, LEFEVRE, Thierry, TREEDE, Hendrik, EGGEBRECHT, Holger, RUBINO, Paolo, MICHEV, Iassen, LANGE, Rüdiger
Format: Article
Language:English
Subjects:
Analysis of Variance
Aortic Valve - diagnostic imaging
Aortic Valve - surgery
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Coronary Restenosis - epidemiology
Coronary Restenosis - surgery
Diseases of the aorta
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Europe
Follow-Up Studies
Heart Valve Diseases - diagnostic imaging
Heart Valve Diseases - surgery
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation - adverse effects
Heart Valve Prosthesis Implantation - instrumentation
Heart Valve Prosthesis Implantation - methods
Heart Valve Prosthesis Implantation - mortality
Humans
Japan
Medical sciences
Multivariate Analysis
Myocardial Revascularization - methods
Myocardial Revascularization - statistics & numerical data
Patient Selection
Radiography
Recurrence
Registries
Reoperation - statistics & numerical data
Risk Factors
Time Factors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transcatheter aortic valve implantation was developed to mitigate the mortality and morbidity associated with high-risk traditional aortic valve replacement. The Edwards SAPIEN valve was approved for transcatheter aortic valve implantation transfemoral delivery in the European Union in November 2007 and for transapical delivery in January 2008. The SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to assess the initial clinical results of the Edwards SAPIEN valve in consecutive patients in Europe after commercialization. Cohort 1 consists of 1038 patients enrolled at 32 centers. Patients who were treated with the transapical approach (n=575) suffered more comorbidities than the transfemoral patients (n=463), resulting in a significantly higher logistic EuroSCORE (29.1% versus 25.7%; P
ISSN:0009-7322
1524-4539
DOI:10.1161/CIRCULATIONAHA.109.907402